These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31488614)

  • 1. Spinal muscular atrophy: Further expanding the clinician's armamentarium.
    Brandsema JF; Sumner CJ
    Neurology; 2019 Oct; 93(14):613-614. PubMed ID: 31488614
    [No Abstract]   [Full Text] [Related]  

  • 2. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Frontiers in the Treatment of Spinal Muscular Atrophy.
    Power CL; O'Rourke DJ
    Ir Med J; 2018 Mar; 111(3):705. PubMed ID: 30376223
    [No Abstract]   [Full Text] [Related]  

  • 5. Current and future treatments of spinal muscular atrophy.
    Smith M
    Dev Med Child Neurol; 2020 Mar; 62(3):267. PubMed ID: 31879942
    [No Abstract]   [Full Text] [Related]  

  • 6. Nusinersen for spinal muscular atrophy: Not just for babies?
    Ciafaloni E; Russman BS
    Neurology; 2019 May; 92(21):985-986. PubMed ID: 31019098
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.
    Richardson RC
    JAMA Pediatr; 2018 Jul; 172(7):701. PubMed ID: 29801053
    [No Abstract]   [Full Text] [Related]  

  • 8. Nusinersen in adults with spinal muscular atrophy: new challenges.
    Mercuri E; Sansone V
    Lancet Neurol; 2020 Apr; 19(4):283-284. PubMed ID: 32199087
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
    Prasad V
    JAMA Pediatr; 2018 Jul; 172(7):701-702. PubMed ID: 29800980
    [No Abstract]   [Full Text] [Related]  

  • 10. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
    Prasad V
    JAMA Pediatr; 2018 Feb; 172(2):123-125. PubMed ID: 29228077
    [No Abstract]   [Full Text] [Related]  

  • 11. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
    Chacko A; Sly PD; Gauld L
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
    [No Abstract]   [Full Text] [Related]  

  • 12. Nusinersen Use in Spinal Muscular Atrophy.
    Pediatrics; 2019 Jan; 143(1):. PubMed ID: 30584063
    [No Abstract]   [Full Text] [Related]  

  • 13. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 14. [Intrathecal Nursinersen Therapy in Children with Spinal Muscular Atrophy and Spinal Deformities].
    Lorenz HM; Kühnle I; Edler J; Hobbiebrunken E; Wilichowski E; Tsaknakis K; Wilken B; Braunschweig L; Hell AK
    Klin Padiatr; 2018 Jul; 230(4):231-233. PubMed ID: 29378349
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Chacko
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624-626. PubMed ID: 31747301
    [No Abstract]   [Full Text] [Related]  

  • 17. Developing therapies for spinal muscular atrophy.
    Wertz MH; Sahin M
    Ann N Y Acad Sci; 2016 Feb; 1366(1):5-19. PubMed ID: 26173388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
    Corey DR
    Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
    [No Abstract]   [Full Text] [Related]  

  • 19. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
    Meylemans A; De Bleecker J
    Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
    Lee M; França UL; Graham RJ; McManus ML
    Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.